Allanson ER, Copson S, Spilsbury K, et al. - Researchers conducted this prospective, double blind, placebo-controlled trial to evaluate the effectiveness of pretreatment with mifepristone before misoprostol, compared with misoprostol alone, for termination of pregnancy after a fetal death in the second trimester. They randomized women needing a termination of pregnancy after fetal death between 14 and 28 weeks of gestation to placebo or 200 mg mifepristone orally 24–48 hours before the termination of pregnancy with misoprostol (400 micrograms every 6 hours vaginally for women at 24 weeks of gestation or less, and 200 micrograms every 4 hours vaginally for women at 24 weeks of gestation or more). Sixty-six women were randomized (34 to placebo and 32 to mifepristone) from April 2013 to November 2016. When compared with misoprostol alone, the sequential use of mifepristone and misoprostol for the termination of pregnancy after fetal deaths between 14 and 28 weeks of gestation reduces the time to delivery while having no adverse effects on maternal complications.